ArticleCells2022
Comprehensive Characterization of Platelet-Enriched MicroRNAs as Biomarkers of Platelet Activation.
Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Donor sex and platelet storage change the therapeutic effects of platelet-derived extracellular vesicles on endothelium.Blood vessels, thrombosis & hemostasis · 2026Article
- Exploration of the expression and regulatory mechanisms of platelet miR-223-3p in hand, foot, and mouth disease (HFMD) complicated by encephalitis.Translational pediatrics · 2026Article
- Platelet microRNA Expression Can Predict Bleeding in HeartMate3 Patients Treated With or Without Aspirin.Journal of cardiovascular translational research · 2025Observational
- Platelet Storage-Problems, Improvements, and New Perspectives.International journal of molecular sciences · 2024Review
- The plasma miRNome and venous thromboembolism in high-grade glioma: miRNA Sequencing of a nested case-control cohort.Journal of cellular and molecular medicine · 2024Article
- Article
- Article
- Serum MicroRNA-191-5p Levels in Vascular Complications of Type 1 Diabetes: The EURODIAB Prospective Complications Study.The Journal of clinical endocrinology and metabolism · 2023Article
- Sources of variability in the human platelet transcriptome.Thrombosis research · 2023Review
- Circulating microRNAs in young individuals with long-duration type 1 diabetes in comparison with healthy controls.Scientific reports · 2023Article
- JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.Journal of cancer research and clinical oncology · 2023Article
- The Novel Role of Noncoding RNAs in Modulating Platelet Function: Implications in Activation and Aggregation.International journal of molecular sciences · 2023Review
- Left ventricular assist devices promote changes in the expression levels of platelet microRNAs.Frontiers in cardiovascular medicine · 2023Article
- The Impact of the Anticoagulant Type in Blood Collection Tubes on Circulating Extracellular Plasma MicroRNA Profiles Revealed by Small RNA Sequencing.International journal of molecular sciences · 2022Article
- Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulation of platelet function is causally connected to thrombus formation and cardiovascular diseases. Therefore, assessing platelet reactivity is crucial. However, current platelet function tests come with pitfalls, limiting clinical use. Plasma miRNA signatures have been suggested as novel biomarkers for predicting/diagnosing cardiovascular diseases and monitoring antiplatelet therapy. Here, we provide results from a comprehensive study on the feasibility of using circulatory platelet miRNAs as surrogate markers of platelet activation. We performed small RNA-Seq on different blood cell types to confirm known and identify novel platelet-enriched miRNAs and validated a panel of 16 miRNAs using RT-qPCR. To identify the main carrier of these blood-based platelet miRNAs, we enriched and analyzed distinct microvesicle populations. Platelets were stimulated with GPVI and P2Y12 agonists in vitro to monitor the release of the selected miRNAs following activation. Finally, the miRNA panel was also measured in plasma from mice undergoing the Folts intervention (recurrent thrombus formation in the carotid artery). Applying an unbiased bioinformatics-supported workflow to our NGS data, we were able to confirm a panel of previously established miRNA biomarker candidates and identify three new candidates (i.e., miR-199a-3p, miR-151a-5p, and miR-148b-3p). Basal levels of platelet-derived miRNAs in plasma were mainly complexed with proteins, not extracellular vesicles. We show that changes in miRNA levels due to platelet activation are detectable using RT-qPCR. In addition, we highlight limitations of studying the in vitro release of miRNAs from platelets. In vivo thrombosis resulted in significant elevations of platelet-derived miRNA levels in mice. In conclusion, we provide in-depth evidence that activated platelets release miRNAs, resulting in measurable changes in circulatory miRNA levels, rendering them promising biomarker candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.